A.E. Lychkova - Dr.Sc. (Med.), Head of the Division, Moscow-s Clinical Research Center of the Department of Health E-mail: lychkova@mail.ru A.M. Puzikov - Collaboratorat the Dividion, Moscow-s Clinical Research Center of the Department of Health

The study included 35 patients aged 15-70 years (mean age 37,6 ± 10,9 years) in IBS-UC (Group 1). The second group in-cluded 42 patients with chronic total ulcerative colitis (group 2) in the acute stage. The control group consisted of 38 pa-tients with IBS, diarrhea occurring in the background. Electromyography recording of ascending, descending colon, and sigmoid colon contractile activity was performed with a 21-channel electroencephalograph (Nihon-Kohden, Neurofax, EEG 4400 series, Washington, DC). In IBS-UC an increase of the frequency of slow wave and spike activity was marked, which clinically manifested as an in-creased intestinal transit and pain. IBS-like syndrome in ulcerative colitis is characterized by diarrhea syndrome, bloating, discomfort and abdominal pain, endoscopic remission of ulcerative colitis, the normal level of C-reactive protein, moderate lymphoplasmacytic infiltration of the mucous membrane of their own, and hypermotor dyskinesia of the colon with severe spastic (pain) activity. Slow wave and spike activity EMG of an ascending colon department of patients with IBS-YUC is almost equal to that of patients with UC in the absence of express endoscopic manifestations of UC. A slow-wave activity of a descending part of the colon of patients with IBS-UC was lesser than that in those with UC, and spike activity, on the contrary, greater, indicating the prevalence of pain in patients with IBS-UC with localization in the descending colon. An increase of the frequency of slow waves in the sigmoid colon of patients with IBS-UC on 10-12% and more may lead re-sult along with other clinical syndromes investigated may lead to the progression of IBS-UC to UC.

 

1. Dignass A., Eliakim R., Magro F., Maaser C., Chowers Y., Geboes K., Mantzaris G., Reinisch W., Colombel J.F., Vermeire S., Travis S., Lindsay J.O., van Assche G. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version) // Rev. Gastroenterol. Mex. 2014. V. 79. № 4. R. 263-89. doi: 10.1016/j.rgmx.2014.10.001. Epub 2014 Dec 6.Spanish. PubMed PMID: 25487134.
2. Kappelman M.D., Rifas-Shiman S.L., Kleinman K. et al. The prevalence and geographic distribution of Crohn-s disease and ulcerative colitis in the United States // Clin. Gastroenterol. Hepatol. 2007. № 5. R. 1424-1429.
3. Loftus E.V. The burden of inflammatory bowel disease in the United States: a moving target - // Clin. Gastroenterol. Hepatol. 2007. № 5.   R. 1383-1384.
4. Patent № 2293516 (RF). Sposob registracii ehlektromotornojj aktivnosti gladkomyshechnykh organov. / A.V. Limancev, A.M. Puzikov.
5. Rachmilevitz D. Coated mesalazine (5-ami­nosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial  // BMJ. 1989. V. 298. Is. 6666. P. 82-86. doi: 10.1136/ bmj.298.6666.82
6. Patent № 2460554 (RF). Sposob terapii jazvennogo kolita i bolezni Krona. / P.L. SHHerbakov, L.B. Lazebnik, I.N. Ruchkina, A.I. Parfenov, O.V. Knjazev, AEH. Lychkova, S.A. Bojjko.
7. Mawe G.M. Colitis-induced neuroplasticity disrupts motility in the inflamed and post-inflamed colon // J. Clin. Invest. 2015. V. 125. № 3. R. 949-955.